1 |
LIANG W H, GUAN W J, CHEN R C, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China[J]. Lancet Oncol, 2020, 21(3): 335-337.
|
2 |
TIAN J, YUAN X, XIAO J, et al. Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre,
|
3 |
YU J, OUYANG W, CHUA M L K, et al. SARS-CoV-2 transmission in patients with cancer at a tertiary care hospital in Wuhan, China[J]. JAMA Oncol, 2020, 6(7): 1108-1110.
|
4 |
ZHANG L, ZHU F, XIE L, et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China[J]. Ann Oncol, 2020, 31(7): 894-901.
|
5 |
DAI M Y, LIU D B, LIU M, et al. Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak[J]. Cancer Discov, 2020, 10(6): 783-791.
|
6 |
FOX T A, TROY-BARNES E, KIRKWOOD A A, et al. Clinical outcomes and risk factors for severe COVID-19 in patients with haematological disorders receiving chemo-or immunotherapy[J]. Br J Haematol, 2020, 191(2): 194-206.
|
7 |
LEE L Y, CAZIER J B, ANGELIS V, et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study[J]. Lancet, 2020, 395(10241): 1919-1926.
|
8 |
PATHANIA A S, PRATHIPATI P, ABDUL B A, et al. COVID-19 and cancer comorbidity: therapeutic opportunities and challenges[J]. Theranostics, 2021, 11(2): 731-753.
|
9 |
JEE J, FOOTE M B, LUMISH M, et al. Chemotherapy and COVID-19 outcomes in patients with cancer[J]. J Clin Oncol, 2020, 38(30): 3538-3546.
|
10 |
ROBILOTTI E V, BABADY N E, MEAD P A, et al. Determinants of COVID-19 disease severity in patients with cancer[J]. Nat Med, 2020, 26(8): 1218-1223.
|
11 |
DE AZAMBUJA E, TRAPANI D, LOIBL S, et al. ESMO management and treatment adapted recommendations in the COVID-19 era: breast cancer[J]. ESMO Open, 2020, 5(Suppl 3): e000793.
|
12 |
黎立喜, 马飞. 《新型冠状病毒肺炎疫情期间乳腺癌合理化诊疗指南》解读[J]. 中国肿瘤临床, 2020, 47(8): 379-383.
|
|
LI L X, MA F. Interpretation of guidelines for the diagnosis and treatment of breast cancer during the COVID-19 outbreak[J]. Chin J Clin Oncol, 2020, 47(8): 379-383.
|
13 |
MARTA G N, POORTMANS P. Moderately hypofractionated breast radiation therapy: is more evidence needed? [J]. Lancet Oncol, 2019, 20(5): e226.
|
14 |
GRADISHAR W J, ANDERSON B O, ABRAHAM J, et al. Breast cancer, version 3.2020, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2020, 18(4): 452-478.
|
15 |
WANG S L, FANG H, SONG Y W, et al. Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial[J]. Lancet Oncol, 2019, 20(3): 352-360.
|
16 |
CURIGLIANO G, BANERJEE S, CERVANTES A, et al. Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus[J]. Ann Oncol, 2020, 31(10): 1320-1335.
|
17 |
SULLIVAN R J, JOHNSON D B, RINI B I, et al. COVID-19 and immune checkpoint inhibitors: initial considerations[J]. J Immunother Cancer, 2020, 8(1): e000933.
|
18 |
DEEKS J J, DINNES J, TAKWOINGI Y, et al. Antibody tests for identification of current and past infection with SARS-CoV-2[J]. Cochrane Database Syst Rev, 2020, 6(6): CD013652.
|
19 |
VAN KAMPEN J J A, VAN DE VIJVER D A M C, FRAAIJ P L A, et al. Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19)[J]. Nat Commun, 2021, 12(1): 267.
|
20 |
RHEE C, KANJILAL S, BAKER M, et al. Duration of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectivity: when is it safe to discontinue isolation? [J]. Clin Infect Dis, 2021, 72(8): 1467-1474.
|
21 |
BULLARD J, DUST K, FUNK D, et al. Predicting infectious severe acute respiratory syndrome coronavirus 2 from diagnostic samples[J]. Clin Infect Dis, 2020, 71(10): 2663-2666.
|
22 |
YU K D, FAN L, QIU L X, et al. Influence of delayed initiation of adjuvant chemotherapy on breast cancer survival is subtype-dependent[J]. Oncotarget, 2017, 8(28): 46549-46556.
|
23 |
胡夕春, 胡志皇, 王碧芸, 等. 新型冠状病毒肺炎与抗肿瘤药物治疗[J]. 中国癌症杂志, 2022, 32(6): 499-511.
|
|
HU X C, HU Z H, WANG B Y, et al. COVID-19 and systemic anti-cancer therapy[J]. Chin Oncol, 2022, 32(6): 499-511.
|
24 |
WEI J L, WU M J, LIU J, et al. Characteristics and outcomes of COVID-19 infection in 45 patients with breast cancer: a multi-center retrospective study in Hubei, China[J]. Breast, 2021, 59: 102-109.
|
25 |
BERSANELLI M. Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors[J]. Immunotherapy, 2020, 12(5): 269-273.
|
26 |
WU Q J, CHU Q, ZHANG H Y, et al. Clinical outcomes of coronavirus disease 2019 (COVID-19) in cancer patients with prior exposure to immune checkpoint inhibitors[J]. Cancer Commun (Lond), 2020, 40(8): 374-379.
|
27 |
LUO J, RIZVI H, EGGER J V, et al. Impact of PD-1 blockade on severity of COVID-19 in patients with lung cancers[J]. Cancer Discov, 2020, 10(8): 1121-1128.
|
28 |
LIÈVRE A, TURPIN A, RAY-COQUARD I, et al. Risk factors for coronavirus disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: a French nationwide cohort study (GCO-002 CACOVID-19)[J]. Eur J Cancer, 2020, 141: 62-81.
|
29 |
WANG B, HUANG Y. Immunotherapy or other anti-cancer treatments and risk of exacerbation and mortality in cancer patients with COVID-19: a systematic review and meta-analysis[J]. Oncoimmunology, 2020, 9(1): 1824646.
|
30 |
DI GIACOMO A M, GAMBALE E, MONTERISI S, et al. SARS-COV-2 infection in patients with cancer undergoing checkpoint blockade: clinical course and outcome[J]. Eur J Cancer, 2020, 133: 1-3.
|
31 |
HU S Y, YIN F Y, NIE L T, et al. Estrogen and estrogen receptor modulators: potential therapeutic strategies for COVID-19 and breast cancer[J]. Front Endocrinol (Lausanne), 2022, 13: 829879.
|
32 |
SAINI K S, LANZA C, ROMANO M, et al. Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy[J]. Br J Cancer, 2020, 123(5): 694-697.
|